Jan Engels

Venture Capital - Life Science | WEF Global Shaper | Entrepreneurship Educator

📍 Germany🔄 Updated September 2026💼 8 investments📅 3 years investing🗓 Last invested Jun 2026
VC🌍 GermanyInvested this quarter
8
Total investments
4
Early stage
2
Mid stage
0
Late stage
3y
Years active

Portfolio

8 investments · sorted by recency
All investments
Early stage
Mid stage
Late stage
Investor & Board Member
Jun 2026
CollimateHealth develops a clinically scalable microbeam radiation technology designed to reshape the way cancer is treated. While conventional radiation oncology typically relies on broader and lower-dose beams that cause significant side effects, microbeam radiation delivers an array of extremely narrow, micrometre-scale beams at substantially higher dose. Tumors exposed to microbeam radiation undergo a form of highly disruptive cell death that increases antigen presentation, which helps to activate an immune response against cancer cells beyond the primary irradiated tumour. In addition, the temporary channels created by microbeam irradiation improve the delivery of therapeutics into tumour tissue, creating synergies with both chemotherapy and immunotherapy.
Investor
Jun 2024
Developing a all-in-one surgical system that makes minimally-invasive procedures more efficient.
Investor
Apr 2024
Sedivention - Fight obesity where it starts! 20 minutes will change your life. A new weight-loss therapy to reduce the hunger feeling – fast, effective, and longterm. No implant, no surgery, no lifelong drug intake.
Investor & Board Observer
Dec 2023
At CustomSurg, we are tackling one of the biggest challenges in modern-day orthopaedic surgery: complex joint fractures. Repairing a joint, shattered into pieces, takes years of training and can only be mastered by the most skilled trauma surgeons. Unfortunately, current clinical outcomes after complex articular trauma are often unsatisfying, with 1 in 4 patients suffering from severe post-operative complications. We are on a mission to change this! Helping surgeons choose and implement the best treatment strategy avoids complications, reduces treatment time and improves surgical outcomes.
Investor
Oct 2023
We support the international clinicians and scientists using Mesenchymal Stromal Cells (MSC) to Ameliorate Severe Complications of inflammation-associated Diseases and which aiming to make MSC-based regenerative therapies an integral part of clinical routine, also in large patient groups and at reasonable cost.
Investor
Sep 2023
Publicly co-funded by the Federal Ministry for Economic Affairs and Climate Action (BMWi) of the German government and the European Social Fonds (ESF). Our mission is to increase the quality of everyday minimally invasive interventions providing the worlds first therapy-assist CT system. Our uncompromised imaging solutions enable safe, intuitive, and efficient procedures for patients and clinicians worldwide. RAYDIAX will provide the worlds first therapy-assist CT system for minimally invasive interventions. The "Interventional Only" - concept enables safe, intuitive, and efficient procedures for both patients, physicians, and hospital employees.
Investor
Jul 2023
ReCatalyst is an EU-level recognized Start-up company and Slovenian Start-up-of-the-year in 2023, which develops and markets services in the field of nanotechnology materials. The company is currently focused on the development and commercialization of next-gen platinum-based catalyst composites for the use in hydrogen fuel cells and will expand its catalyst production platform also to other related areas for decarbonization of the energy and transport sectors such as water electrolysis as well as other Power to X applications. The company has established development collaborations with some of the most reputable companies in the field in five of the G7 economies and is supported by the prestigious European EIC Transition financing, as well as a EUR 1.7M investment from international investors.
Investor & Board Observer
Mar 2023
We founded mbiomics to improve peoples lives by providing a novel approach to fully understand the secrets of the microbiome with the goal to better inform targeted therapies and how to lead a healthy life.
Experience · 10 entries
All (10)
Investments (8)
Founder (1)
Board (3)
2026
Investor & Board Member
Jun 2026
CollimateHealth develops a clinically scalable microbeam radiation technology designed to reshape the way cancer is treated. While conventional radiation oncology typically relies on broader and lower-dose beams that cause significant side effects, microbeam radiation delivers an array of extremely narrow, micrometre-scale beams at substantially higher dose. Tumors exposed to microbeam radiation undergo a form of highly disruptive cell death that increases antigen presentation, which helps to activate an immune response against cancer cells beyond the primary irradiated tumour. In addition, the temporary channels created by microbeam irradiation improve the delivery of therapeutics into tumour tissue, creating synergies with both chemotherapy and immunotherapy.
2024
Investor
Jun 2024
Developing a all-in-one surgical system that makes minimally-invasive procedures more efficient.
Investor
Apr 2024
Sedivention - Fight obesity where it starts! 20 minutes will change your life. A new weight-loss therapy to reduce the hunger feeling – fast, effective, and longterm. No implant, no surgery, no lifelong drug intake.
2023
Investor & Board Observer
Dec 2023
At CustomSurg, we are tackling one of the biggest challenges in modern-day orthopaedic surgery: complex joint fractures. Repairing a joint, shattered into pieces, takes years of training and can only be mastered by the most skilled trauma surgeons. Unfortunately, current clinical outcomes after complex articular trauma are often unsatisfying, with 1 in 4 patients suffering from severe post-operative complications. We are on a mission to change this! Helping surgeons choose and implement the best treatment strategy avoids complications, reduces treatment time and improves surgical outcomes.
Investor
Oct 2023
We support the international clinicians and scientists using Mesenchymal Stromal Cells (MSC) to Ameliorate Severe Complications of inflammation-associated Diseases and which aiming to make MSC-based regenerative therapies an integral part of clinical routine, also in large patient groups and at reasonable cost.
Show all 10 entries ↓
Investment activity
2023–2026 · 8 investments
202352024220261
Recent (last 2 years)Earlier